Globus Medical, Inc. with ticker code (GMED) now have 11 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between 77 and 58 suggesting an average Analsyt target price of $66.36. Now with the previous closing price of $50.01 this now indicates there is a potential upside of 32.7%. The 50 day moving average now sits at $56.70 while the 200 day moving average is $60.90. The market capitalization for the company is 7.21B. The current share price for the company is: 51.6 USD
The potential market cap would be $9,570,712,198 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 25.29, revenue per share of 10.96 and a 7.51% return on assets.
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions. The Company’s product categories include Musculoskeletal Solutions and Enabling Technologies. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the majority of conditions affecting the spine, including degenerative conditions, deformity, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery (MIS) techniques. It includes traditional fusion implants, such as pedicle screws and rod systems. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip. Enabling Technologies is comprised of imaging, navigation and robotics (INR) solutions for assisted surgery.
